Condensed Consolidated Statements of Operations - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Condensed Consolidated Statements of Operations
Net Revenues	$ 52,061	$ 52,979	$ 155,207	$ 151,223
Operating Expenses
Cost of sales (excluding depreciation and amortization)	24,413	20,118	66,712	62,617
Research and development	2,456	2,939	8,229	12,318
Selling, general, and administrative	17,181	15,725	53,588	50,621
Depreciation and amortization	11,346	11,358	33,568	33,739
Legal settlement expense			8,400	0
Purified Cortrophin Gel pre-launch charges	227	37	780	8,275
Total Operating Expenses	55,623	50,177	171,277	167,570
Operating (Loss)/Income	(3,562)	2,802	(16,070)	(16,347)
Other Expense, net
Interest expense, net	(2,497)	(2,510)	(7,482)	(6,898)
Other expense, net	(1,071)	(229)	(1,653)	(335)
(Loss)/Income Before Benefit for Income Taxes	(7,130)	63	(25,205)	(23,580)
Benefit for income taxes	2,683	371	6,738	4,667
Net (Loss)/Income	$ (4,447)	$ 434	$ (18,467)	$ (18,913)
Basic and Diluted (Loss)/Earnings Per Share:
Basic (Loss)/Earnings Per Share	$ (0.37)	$ 0.04	$ (1.53)	$ (1.58)
Diluted (Loss)/Earnings Per Share	$ (0.37)	$ 0.04	$ (1.53)	$ (1.58)
Basic Weighted-Average Shares Outstanding	12,107	11,991	12,066	11,953
Diluted Weighted-Average Shares Outstanding	12,107	12,003	12,066	11,953